FY2025 EPS Estimates for FDMT Boosted by Cantor Fitzgerald

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT - Free Report) - Equities researchers at Cantor Fitzgerald upped their FY2025 EPS estimates for shares of 4D Molecular Therapeutics in a note issued to investors on Tuesday, March 4th. Cantor Fitzgerald analyst J. Schimmer now expects that the company will post earnings per share of ($3.22) for the year, up from their prior forecast of ($3.46). The consensus estimate for 4D Molecular Therapeutics' current full-year earnings is ($2.84) per share.

4D Molecular Therapeutics (NASDAQ:FDMT - Get Free Report) last issued its quarterly earnings data on Friday, February 28th. The company reported ($0.90) earnings per share for the quarter, missing analysts' consensus estimates of ($0.80) by ($0.10).

A number of other research firms have also recently issued reports on FDMT. BMO Capital Markets cut shares of 4D Molecular Therapeutics from an "outperform" rating to a "market perform" rating and dropped their price target for the company from $40.00 to $15.00 in a research note on Monday, January 13th. Weiss Ratings restated a "sell (d-)" rating on shares of 4D Molecular Therapeutics in a research report on Friday. Royal Bank of Canada decreased their price target on shares of 4D Molecular Therapeutics from $39.00 to $35.00 and set an "outperform" rating on the stock in a research note on Monday, March 3rd. HC Wainwright restated a "buy" rating and issued a $36.00 target price on shares of 4D Molecular Therapeutics in a research report on Monday, March 3rd. Finally, Chardan Capital dropped their price target on 4D Molecular Therapeutics from $30.00 to $28.00 and set a "buy" rating for the company in a research report on Tuesday, March 4th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and seven have issued a buy rating to the stock. According to data from MarketBeat.com, 4D Molecular Therapeutics currently has an average rating of "Moderate Buy" and an average price target of $30.63.

Remove Ads

4D Molecular Therapeutics Price Performance

NASDAQ FDMT traded down $0.18 during trading hours on Thursday, reaching $3.89. The company's stock had a trading volume of 829,356 shares, compared to its average volume of 799,182. The firm has a market capitalization of $180.11 million, a price-to-earnings ratio of -1.36 and a beta of 2.83. The company's 50-day moving average is $5.05 and its two-hundred day moving average is $8.17. 4D Molecular Therapeutics has a 1-year low of $3.85 and a 1-year high of $36.25.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in FDMT. KLP Kapitalforvaltning AS purchased a new stake in shares of 4D Molecular Therapeutics in the 4th quarter valued at approximately $48,000. Point72 Asia Singapore Pte. Ltd. purchased a new stake in shares of 4D Molecular Therapeutics during the fourth quarter worth approximately $50,000. PNC Financial Services Group Inc. raised its holdings in 4D Molecular Therapeutics by 66.1% in the fourth quarter. PNC Financial Services Group Inc. now owns 9,124 shares of the company's stock valued at $51,000 after acquiring an additional 3,630 shares in the last quarter. Daiwa Securities Group Inc. lifted its stake in 4D Molecular Therapeutics by 5,291.8% in the fourth quarter. Daiwa Securities Group Inc. now owns 9,921 shares of the company's stock worth $55,000 after acquiring an additional 9,737 shares during the last quarter. Finally, Proficio Capital Partners LLC purchased a new stake in shares of 4D Molecular Therapeutics in the 3rd quarter valued at approximately $108,000. 99.27% of the stock is currently owned by institutional investors and hedge funds.

4D Molecular Therapeutics Company Profile

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.